Flowsion has just received the CE mark for it’s for it’s Glycostat® system as of May 2021. The Glycostat® base unit, microdialys probe, and consumable kit are class 2b, class 3, and class 1, respectively.
Flowsion has received approval of the GLUCOSTAT project under the EU SME programme.
In that respect Flowsion has received a grant of m€ 2.5.
Flowsion will during the GLUCOSTAT project period from 2017 to 2019 develop and get the CE mark for the closed loop system named GLYCOSTAT®.
GLYCOSTAT will be able to act like an artificial pancreas in that it will automatically control the blood glucose concentration of ICU patient to remain in the range determined by the ICU doctors and nurses.
It has been shown that the mortality, morbidity, length of stay, and general costs related to ICU patients are drastically reduced (30-40%) when the blood glucose concentration of ICU patients are kept within the normal range.
The GLUCOSTAT project has received funding from the European Union’s Horizon 2020 research and innovation
programme under grant agreement 777691
Kontakt os
About
Flowsion is a medical device company focused on the design, development and commercialization of a product platform specifically for the in-hospital automated glucose control and continuous glucose monitoring market.
